ResApp Health (ASX:RAP) has some clinical study results on the table, with the ASX granting the company a trading halt to prepare.
ResApp is developing the world’s first clinically-tested, regulatory-approved respiratory disease diagnostic test for smartphones.
The halt will remain in place until the opening of trade on Wednesday 30th September 2015, or earlier if an announcement is made to the market.
Proactive Investors Australia is the market leader in producing news, articles and research reports on ASX emerging companies with distribution in Australia, UK, North America and Hong Kong / China.